Kelley et al. (2005) conducted apoptosis experiments comparing TRAIL variants bound solely to DR4 or DR5, and revealed that lung, colon, and breast cancer cell lines show similarity in the membrane surface expression levels of DR4 and DR5 and exhibit more significant sensitivity to specific mutants of DR5 (Kelley et al., 2005). And the preferential agonistic DR5 antibody reactivity of ovarian, colon, and renal cell carcinoma cell lines is closely related to their high surface DR5 expression levels (Zeng et al., 2006; Nawrocki et al., 2007; Saulle et al., 2007; Marini et al., 2006). Here, TNFRSF10B is linked to breast cancer.